Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral hPTH(1-34) Formulations vs. Forteo in Healthy Males
NCT05965167Phase 1Completed
- Sponsor
- Entera Bio Ltd.
- Start
- May 2023
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teriparatide in hypoparathyroidism, osteoporosis and bone fracture (Fx), sponsored by Entera Bio Ltd. Started May 2023; status: completed.
02
Drugs
teriparatide
03
Conditions
hypoparathyroidismosteoporosisbone fracture (Fx)
Beyond the preview
Go deeper on NCT05965167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965167.